- Home
- ADXN vs NLSP Comparison
ADXN vs NLSP Comparison
Compare ADXN & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- NLSP
- Stock Information
- Founded
- ADXN 2002
- NLSP 2015
- Country
- ADXN Switzerland
- NLSP Switzerland
- Employees
- ADXN N/A
- NLSP N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- NLSP Health Care
- Exchange
- ADXN Nasdaq
- NLSP Nasdaq
- Market Cap
- ADXN 10.1M
- NLSP 12.4M
- IPO Year
- ADXN N/A
- NLSP 2021
- Fundamental
- Price
- ADXN $8.83
- NLSP $2.10
- Analyst Decision
- ADXN Strong Buy
- NLSP
- Analyst Count
- ADXN 1
- NLSP 0
- Target Price
- ADXN $30.00
- NLSP N/A
- AVG Volume (30 Days)
- ADXN 14.4K
- NLSP 275.3K
- Earning Date
- ADXN 08-11-2025
- NLSP 07-22-2025
- Dividend Yield
- ADXN N/A
- NLSP N/A
- EPS Growth
- ADXN N/A
- NLSP N/A
- EPS
- ADXN 0.10
- NLSP N/A
- Revenue
- ADXN $278,508.00
- NLSP N/A
- Revenue This Year
- ADXN $86.57
- NLSP N/A
- Revenue Next Year
- ADXN N/A
- NLSP N/A
- P/E Ratio
- ADXN $0.78
- NLSP N/A
- Revenue Growth
- ADXN N/A
- NLSP N/A
- 52 Week Low
- ADXN $6.51
- NLSP $1.30
- 52 Week High
- ADXN $13.27
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- ADXN 49.41
- NLSP 46.61
- Support Level
- ADXN $8.78
- NLSP $2.20
- Resistance Level
- ADXN $9.89
- NLSP $3.08
- Average True Range (ATR)
- ADXN 0.67
- NLSP 0.25
- MACD
- ADXN -0.03
- NLSP -0.06
- Stochastic Oscillator
- ADXN 43.01
- NLSP 8.40
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.